OncoMethylome Sciences Changes its Name to MDxHealth
OncoMethylome Sciences SA announced that its Extraordinary General Shareholders' Meeting passed the resolution on the proposed name change of the company to MDxHealth SA. The name change was unanimously supported by the shareholders present or represented at the meeting.
As announced in the 2010 half-year results, MDxHealth is finalizing a new strategy that focuses on high-value oncology based molecular diagnostic testing for personalized medicine. The aim of this new strategy is to reap the full benefits of the company's world-leading methylation platform by developing DNA-biomarkers as stand-alone cancer diagnostics. The company has moved away from its original model as a pure discovery company which out-licensed biomarkers to third party developers and distributors. In the new strategy, the company will end-develop products itself and sell them directly to treating physicians and to pharmaceutical companies. This new strategy will enable the company to control product development and sales rather than being entirely dependent on partners.
To fully reflect the change in strategy and better position the company towards patients, physicians and new pharmaceutical partners, management and the Board of Directors proposed MDxHealth as the new name of the company. The name change is particularly important for the company's direct sales to treating physicians who want healthcare solutions. The company believes that "MDxHealth" captures its new aspirations. "MDx", short for molecular diagnostics, has rapidly become one of the key areas of healthcare innovation and progress; an area where diagnostics and therapeutics converge. While "Health" is really what the company's work is all about: assisting physicians to improve the life and health of cancer patients. "MDxHealth" conveys the company's renewed mission: to develop and commercialize advanced molecular diagnostic tests for personalized cancer treatment.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Squeezing low-cost electricity from sustainable biomaterial
Cowpea_Chlorotic_Mottle_Virus

Key enzyme for production of second-generation ethanol discovered in Brazilian Amazon
Oryzias_latipes
Severe_combined_immunodeficiency

SARS-CoV-2: Antiviral treatment promotes emergence of new variants - Analysis of genomic diversity in prolonged infections

Old and new challenges for food safety
Intercell reports positive results from its Phase II Pseudomonas aeruginosa investigational vaccine study
Livatag follow up demonstrates significant survival increase in advanced hepatocellular carcinoma patients
Analytica Vietnam 2017: More exhibitors and a strong supporting program

Giant snails as pets can be dangerous - They are both scary and fascinating at the same time. Giant snails are becoming increasingly popular as pets. Now researchers are warning
